Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
22.45
-0.82 (-3.52%)
Mar 31, 2025, 1:39 PM EDT - Market open

Edgewise Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
31.8723.4517.6311.032.21
Upgrade
Research & Development
126.9790.9154.0332.1914.98
Upgrade
Operating Expenses
158.83114.3671.6643.2217.19
Upgrade
Operating Income
-158.83-114.36-71.66-43.22-17.19
Upgrade
Interest & Investment Income
25.0214.194.020.40.07
Upgrade
Pretax Income
-133.81-100.16-67.64-42.81-17.12
Upgrade
Net Income
-133.81-100.16-67.64-42.81-17.12
Upgrade
Net Income to Common
-133.81-100.16-67.64-42.81-17.12
Upgrade
Shares Outstanding (Basic)
926454381
Upgrade
Shares Outstanding (Diluted)
926454381
Upgrade
Shares Change (YoY)
45.02%18.90%42.82%4977.96%95.63%
Upgrade
EPS (Basic)
-1.45-1.57-1.26-1.14-23.17
Upgrade
EPS (Diluted)
-1.45-1.57-1.26-1.14-23.17
Upgrade
Free Cash Flow
-110.34-97.69-58.18-34.18-14.84
Upgrade
Free Cash Flow Per Share
-1.19-1.53-1.09-0.91-20.08
Upgrade
EBITDA
-156.76-112.81-71.29-42.94-17.01
Upgrade
D&A For EBITDA
2.071.550.370.270.19
Upgrade
EBIT
-158.83-114.36-71.66-43.22-17.19
Upgrade
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q